Tuesday, October 6, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· September 30, 2026

Mattel Announces Roger Lynch as Chairman and Chief Executive Officer Succeeding Ynon Kreiz

View original at finance.yahoo.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ynon Kreiz leaves a legacy of transitioning Mattel from a toy manufacturer to a leading IP-driven play and family entertainment company, and the Board is confident Lynch and the Mattel team will build on that foundation and advance the strategy to leverage the iconic brand portfolio.

    60% confidence

  • Lynch is honored by the Board's confidence and excited to lead the Mattel team, having admired Mattel's brands, people, and culture during his years on the Board.

    60% confidence

  • During Kreiz's tenure, Mattel leveraged the power of its world-class brands, attracted exceptional entertainment partners, and strengthened its balance sheet; the company is well positioned for its next phase of profitable growth.

    60% confidence

  • Under Lynch's leadership, Condé Nast unified global operations and expanded and tailored IP monetization opportunities for its brands, driving significant and consistent profit growth since 2020.

    60% confidence

  • Roger Lynch is a visionary leader with a track record of growing global companies at the forefront of changing industry and consumer trends, and has been an invaluable contributor to shaping the company's direction amid its expansion into entertainment and digital products.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com